Ophthalmology company Oraya Therapeutics will collaborate with researchers from Boston's Dana-Farber Cancer Institute to study applications of its novel radiation therapy against cancer when used in conjunction with gold nanoparticles.
Wet age-related macular degeneration is the leading cause of blindness in the developed world. The standard of care calls for about 8 costly injections into the eye of medication containing anti-VEGF (vascular endothelial growth factor) per year. "In the real world having patients maintain that level of monitoring and therapy just does not happen," Jim Taylor, who has struggled to convince his aging mother to receive the therapy, told FierceMedicalDevices in an interview.
The National Institutes of Health (NIH) has awarded $14.5 million in eight grants to researchers working to develop high quality and low cost DNA sequencing. The grants are each for two to four years and are awarded through the Advanced DNA Sequencing Technology program of the National Human Genome Research Institute, a part of NIH.
While Google-backed personal genetics startup 23andMe is still working through its disagreements with the FDA, the company has impressed another part of the federal machine enough to win funding.
A decade of flat funding compounded by last year's federal sequester cuts has put U.S. biomedical research in a pinch in recent years, but under a new bill the National Institutes of Health would be spared the budget ax.
The CRO unit of nonprofit researcher SRI International has paired up with NIH's National Institute of Allergy and Infectious Diseases, signing a $49 million contract to handle preclinical work on potential treatments for HIV.
In 2008, the U.S. National Institutes of Health began releasing to the public how much the agency spends in various research categories. I decided to pick out the top-funded disease areas to get a sense of what disorders and diseases the U.S. government is prioritizing.
The discovery of vials of "variola," commonly known as smallpox, in a storage room at the National Institutes of Health in Bethesda, MD, has raised new concerns that the virus could be used in a bioterrorism attack.
Having played a pioneering role collaborating with the NIH on a new drug for sickle cell disease, Newton, MA-based AesRx has moved up the food chain after completing a buyout deal with Baxter International.
Nature reports that the NIH will soon unveil a $248 million to develop new 'electroceuticals,' therapeutic implants that can treat disease by stimulating nerves.